PAREXEL and SHYFT Analytics Partner to Deliver Faster, More Dynamic Real-World Data Studies
November 08 2018 - 8:30AM
Business Wire
SHYFT’s leading platform to become PAREXEL’s foundation for
outcomes analysis in support of clinical development and
commercialization
SHYFT Analytics, a Medidata Solutions (NASDAQ:MDSO) company, and
PAREXEL International, a leading innovator of global
biopharmaceutical services, today announced that the companies have
entered into a strategic partnership that establishes SHYFT’s
technology as an integral part of PAREXEL’s foundation for
Real-World Evidence (RWE) generation and outcomes research for
biopharmaceutical and medical device clients.
The collaboration combines PAREXEL’s innovative scientific and
clinical services with SHYFT’s market-leading suite of RWE products
to provide insights and outcomes from patient-level data more
efficiently to customers worldwide. The pairing aims to optimize
the design and execution of ongoing and retrospective clinical
studies, from late-phase research to safety studies to the support
of pragmatic clinical trials.
SHYFT’s QUANTUM Real-World Evidence platform allows researchers
to generate robust “submission-ready” studies 92% faster than
industry standard, on average. PAREXEL will be leveraging the SHYFT
platform to perform at-scale analyses including cohort modeling,
trial feasibility assessment, and large scale observational studies
- research that will have broad impact across the drug development
and Market Access spectrum. The relationship builds upon PAREXEL’s
real-world data strategy that integrates data access, advanced
technologies, data science capabilities, and clinical and
consulting expertise.
“PAREXEL is, and always has been, committed to helping sponsor
organizations navigate the complexities of drug development,” said
Michelle Hoiseth, Chief Data Officer for PAREXEL. “The growing
availability of real-world data combined with innovative analytics
methods and groundbreaking technologies present an opportunity to
assist our organization in delivering on that commitment. As we
have evaluated capabilities in this area, we have found SHYFT’s
platform to be unmatched among other RWE platforms, in its ability
to provide answers to complex scientific and commercial queries
quickly, with repeatable precision, in a user-friendly manner. By
leveraging SHYFT’s platform, our teams will be able to generate
real-time insights spanning strategic consulting to pivotal trial
feasibility to late-phase health economics and outcomes research
(HEOR) analytics with a much higher level of efficiency. This,
combined with our enhanced data linking capabilities, is a
significant step forward in our approach to help sponsors leverage
real-world data in a meaningful way now and in the future.”
“The potential for real-world evidence to drive innovation and
value in healthcare is enormous,” said Zack King, EVP Medidata and
President of SHYFT. “The adoption, integration, and analysis of
real-world data (RWD) has broad use cases across drug development
and commercialization and SHYFT’s technology was designed to meet
this growing need. We look forward to collaborating with PAREXEL’s
industry experts as they lead the way in delivering RWD based
solutions for biopharmaceutical and medical device companies.”
SHYFT will be joining PAREXEL at booth #211 at the ISPOR Europe
2018 conference focused on health economics and outcomes research
(HEOR), taking place in Barcelona November 10-14.
About SHYFT
SHYFT Analytics, a Medidata company, is the leading platform for
commercial and real-world data analytics with products designed
specifically for the pharmaceutical, biotech, and medical device
industry. SHYFT’s data analytics platform is the most efficient and
scalable way to transform massive amounts of complex healthcare
data into on-demand clinical and commercial insight. SHYFT is
headquartered in Boston with offices in San Francisco and New York
City. Learn more about SHYFT at www.shyftanalytics.com, or follow
the company on Twitter @SHYFTAnalytics or LinkedIn.
About Medidata
Medidata is leading the digital transformation of life sciences
with the world's most-used platform for clinical development,
commercial and real-world data. Powered by artificial intelligence
and delivered by #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users every day to create hope for millions of
patients. Discover the future of life sciences: www.mdsol.com
About PAREXEL International
PAREXEL International Corporation is a leading innovator of
global biopharmaceutical services. We simplify our clients’ journey
of transforming scientific discoveries into new medical treatments
for patients with high-quality Phase I-IV clinical research,
regulatory, consulting and market access services. PAREXEL develops
breakthrough innovations and solutions by leveraging its
comprehensive therapeutic, technical and functional expertise, in
more than 100 countries around the world. For more information
visit www.PAREXEL.com.
PAREXEL is a registered trademark of PAREXEL International
Corporation. All other trademarks are the property of their
respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181108005416/en/
Medidata:Investors:Betsy Frank, +1
917-522-4620bfrank@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024